SXTP

60 degrees pharmaceuticals, Inc.

• TipRanks·5d ago

  60 Degrees Pharmaceuticals to conclude enrollment in tafenoquine study

• Benzinga·5d ago

  60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027

• TipRanks·5d ago

  60 Degrees highlights interim tafenoquine data, caps enrollment

• Benzinga·5d ago

  60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?

• NASDAQ·5d ago

  Babesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares Climb

• Benzinga·5d ago

  12 Health Care Stocks Moving In Monday's After-Market Session

• Benzinga·10/01 12:12

  60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6

• TipRanks·09/14 20:32

  60 Degrees Advances Babesiosis Treatment With FDA Submission

• Benzinga·09/14 20:11

  60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027

• TipRanks·09/08 21:07

  60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases

• Benzinga·09/08 21:06

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• Benzinga·08/27 21:07

  12 Health Care Stocks Moving In Thursday's After-Market Session

• TipRanks·08/17 15:30

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

• NASDAQ·08/17 09:23

  60 Degrees Pharma Q2 Net Loss Widens Despite 106% Product Revenue Growth; Stock Up

• Benzinga·08/14 19:48

  60 Degrees Q2 EPS $(0.90) Misses $(0.86) Estimate, Sales $56.798K Miss $186.000K Estimate